Read about Dr. Verma's research, clinical trials, and national honors across major publications.
Dr. Subodh Verma shares his perspective on screening, lifestyle changes, and reducing cardiovascular disease risk.
Read Article
Featured in The Globe and Mail's Report on Business, highlighting Dr. Verma's early career achievements and recognition as a leading cardiac surgeon.
Read Article
Honored in 2009 as one of Canada's Top 40 Under 40 for his outstanding contributions as a Cardiac Surgeon at St. Michael's Hospital and Canada Research Chair at the University of Toronto.
Read Article
Dr. Subodh Verma co-led the landmark NEWTON-CABG CardioLink-5 trial, a first-of-its-kind international study testing PCSK9 inhibitors in patients undergoing open-heart surgery.
Read Article
A new study co-authored by Dr. Subodh Verma suggests that the accelerated timeline for heart disease in South Asians may lie with faulty repairs to blood vessel damage.
Read Article
A Heart and Stroke Foundation report warns that heart disease can occur with no signs or symptoms, and Dr. Subodh Verma emphasizes the critical importance of knowing your risk factors.
Read Article
Glenn Dennis celebrates a new lease on life and his Valentine's Day birthday after Dr. Subodh Verma performed a life-saving emergency surgery to treat a severe heart infection.
Read Article.svg)
Two studies led by Dr. Subodh Verma suggest that BRCA1 and BRCA2 gene mutations, known to raise breast cancer risk, may also increase the risk of developing heart disease.
Read Article
Dr. Subodh Verma, who led the SELECT trial in Canada, discusses how semaglutide provides critical cardiovascular protection independent of weight loss, urging expanded drug coverage.
Read ArticleDr. Subodh Verma highlights the aggressive nature of heart disease in young South Asians, emphasizing that ethnicity itself is a major risk factor requiring earlier screening.
Read Article
A new study led by researchers at Unity Health Toronto and the University of Toronto suggests that South Asian patients have deficient vessel repair capabilities, which may contribute to their excess cardiovascular risk.
Read Article
Why are some otherwise healthy South Asians increasingly vulnerable to heart disease? A massive international study has found people native to South Asia can die from heart disease five to 10 years earlier than other ethnic groups.
Read Article
Semaglutide, known as Ozempic when prescribed for diabetes, can significantly improve symptoms in patients with obesity-related heart failure and help them lose weight, research shows.
Read Article
The NEWTON-CABG CardioLink-5 trial, a first-of-its-kind international study co-led by St. Michael's Hospital, tested whether intensive cholesterol reduction could protect vein grafts after open-heart surgery.
Read Article
Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial, evaluating adults with reduced ejection fraction.
Read Article
Results from the STRIDE clinical trial co-led by Dr. Subodh Verma show that semaglutide (Ozempic) significantly improves symptoms and functional capacity in patients with peripheral artery disease and diabetes.
Read Article
A new study from St. Michael's Hospital shows how a class of diabetes medications (SGLT2 inhibitors) can protect against heart disease by restoring regenerative progenitor cells and reducing inflammation.
Read Article
The DAPA-HF trial, co-led in Canada by Dr. Subodh Verma, found that the diabetes medication dapagliflozin significantly reduced the risk of heart disease-related death and worsening heart failure, even in patients without diabetes.
Read Article
A new study co-led by Dr. Subodh Verma and published in the New England Journal of Medicine found that the medication semaglutide can significantly improve symptoms, physical limitations and exercise function in patients with a common type of heart failure.
Read Article
Dr. Subodh Verma formed CARDIOLINK, a research hub bringing together top experts to address major themes of cardiovascular surgery and deliver definitive, practice-changing results.
Read Article
The PACT-MEA study, led by Dr. Subodh Verma, provides a rare contemporary estimate of cardiovascular risk in people living with diabetes in the Middle East and South Africa, highlighting a critical need for global representation in clinical research.
Read Article
Visceral adiposity plays a primordial role in the development and clinical course of HFpEF. People living with obesity-associated HFpEF tend to have a greater symptom burden and worse outcomes.
Read Article
A post-hoc analysis of the STRIDE trial shows that semaglutide (Ozempic) improved walking capability in patients with peripheral arterial disease and type 2 diabetes, regardless of diabetes duration, BMI, or glycemic control.
Read Article.JPG)
Dr. Subodh Verma established the John McNeill Excellence in Health Research Mentorship Award at UBC to recognize exceptional mentorship and honor his graduate supervisor, Dr. John McNeill.
Read ArticleDr. Subodh Verma, MD’00 is an internationally renowned cardiac surgeon-scientist who is an active contributor to Canadian clinical practice guidelines and has co-authored recommendations for atrial fibrillation, antiplatelet therapy, cardiorenal protection, diabetes, heart failure, and peripheral artery disease.
Read ArticleWatch Dr. Verma's keynote presentations, clinical trial announcements, podcast interviews, and expert panel discussions.
Dr. Verma expresses his gratitude to his family, surgical partners, students, collaborators, and mentors upon receiving the CCS annual research award and CSCS annual achievement award.
Dr. Subodh Verma shares his passion for collaboration, mentorship, and grooming the next generation of medical students and researchers.
Dr. Subodh Verma discusses the primary results from the SEARCH-AF Cardiolink Randomized Trial, assessing enhanced cardiac rhythm monitoring following heart surgery.
Dr. Subodh Verma speaks about heart health, patient stories, heart disease risks, and more on the Beyond the Script podcast.
Dr. Verma discusses the paradigm-shifting role of SGLT2 inhibitors in cardiorenal protection and diabetes management.
2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation, featuring Dr. Subodh Verma.
St. Michael's Hospital Cardiology Grand Rounds featuring Dr. Subodh Verma discussing the STRIDE trial and semaglutide for peripheral arterial disease.
Join Professor Subodh Verma for key highlights in heart failure and cardiometabolic disease from the American Heart Association Scientific Sessions 2022.
Dr. Subodh Verma and Dr. Lawrence Leiter discuss findings from the NEWTON-CABG CardioLink-5 study on evolocumab and saphenous vein graft patency.
Dr. Harlan Krumholz and Dr. Subodh Verma discuss sex differences in semaglutide benefits for obesity-related heart failure with preserved ejection fraction.
A CTV feature with Dr. Subodh Verma and a patient discussing the unique cardiovascular risks women face, risk reduction, and the role of inflammation.
Dr. Marc P. Bonaca, Dr. Subodh Verma, and Dr. A. Michael A. Lincoff discuss semaglutide's consistent reduction of cardiovascular outcomes after CABG surgery.
Dr. Subodh Verma discusses findings from the SEMA-VR CardioLink-15 trial on semaglutide enhancing vasculogenic repair processes.
Dr. Subodh Verma and Dr. Lawrence A. Leiter present a post-AHA update on PCSK9 inhibitors, reviewing clinical trial evidence and outcomes.
Dr. Subodh Verma discusses glycaemic management and cardiovascular risk reduction in individuals with type 2 diabetes.
Drs. Subodh Verma, Marc Bonaca, and Alice Cheng discuss the landmark STRIDE study evaluating semaglutide for peripheral arterial disease.
Dr. Subodh Verma discusses the first randomized trial evaluating the effect of an SGLT2 inhibitor on left ventricular structure and function using cardiac MRI.
Dr. Subodh Verma and Dr. Supratik Bhattacharyya discuss the landmark STRIDE trial exploring the effects of Semaglutide on peripheral artery disease (PAD) outcomes.
Reach out to discuss speaking, interviews, or partnership opportunities.
![[background image]](https://cdn.prod.website-files.com/image-generation-assets/7aec9f70-e14f-43e7-a4bf-4098f770209d.avif)
